Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.83 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL333873 | 0.96 | — | — | |
| Malonic Acid SCHEMBL431221 | 0.96 | — | — | |
| Malonic Acid SCHEMBL957647 | 0.92 | CA4 (0.83) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL22466326 | 0.92 | — | — | |
| Malonic Acid SCHEMBL4365583 | 0.92 | CA4 (0.83) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL954992 | 0.92 | CA4 (0.83) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL955599 | 0.92 | CA4 (0.83) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL19714757 | 0.87 | CA4 (0.91) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL2475920 | 0.87 | CA4 (0.91) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL3190631 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993569-B1 | ANTI-AGING TREATMENT USING COPPER AND ZINC COMPOSITIONS | OMP INC (US) | 2014-07-23 | — | — | EP | claimed |
| EP-4262528-B1 | DEVICE AND METHOD FOR CONTINUOUS EVEN APPLICATION OF COMPOSITION TO SKIN | KENVUE BRANDS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12472336-B2 | System and method for selective application of cosmetic composition to impart undereye brightening | KENVUE BRANDS LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-12358008-B2 | Device for supplying a composition to a pressurized deposition system | KENVUE BRANDS LLC (US) | 2025-07-15 | — | — | US | disclosed |
| CN-114206426-B | Device and method for applying a cosmetic composition by means of a grated end effector | 强生消费者公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12178978-B2 | Device and method for application of cosmetic compositions through a grated end effector | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-113226158-B | Apparatus and method for selectively applying topical compositions using dynamic thresholds | 强生消费者公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240335645-A1 | SYSTEM AND METHOD FOR SELECTIVE APPLICATION OF COSMETIC COMPOSITION TO IMPART UNDEREYE BRIGHTENING | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4013294-B1 | DEVICE AND METHOD FOR APPLICATION OF COSMETIC COMPOSITIONS THROUGH A GRATED END EFFECTOR | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3917680-B1 | DEVICE FOR SUPPLYING A COMPOSITION TO A PRESSURIZED DEPOSITION SYSTEM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20220032025-A1 | SYSTEM AND METHOD FOR SELECTIVE APPLICATION OF COSMETIC COMPOSITION TO IMPART UNDEREYE BRIGHTENING | KENVUE BRANDS LLC | 2022-02-03 | — | — | US | disclosed |
| CN-111615385-A | Compositions and methods for treating emphysema and other forms of COPD | 肺气肿解决方案私人有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-1816116-B3 | Chemical compositions and methods of making them | OMP INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8952057-B2 | Compositions for anorectal use and methods for treating anorectal disorders | JR CHEM, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| EP-1816116-B1 | Chemical compositions and methods of making them | JR CHEMICALS (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20120177583-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | JR CHEM, LLC | 2012-07-12 | — | — | US | disclosed |
| US-20110178318-A1 | METHODS OF MAKING BIMETAL COMPLEXES | RAMIREZ JOSE E | 2011-07-21 | — | — | US | disclosed |
| US-7897800-B2 | Chemical compositions and methods of making them | JR CHEM, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-30 | — | — | US | disclosed |
| EP-1816116-A1 | Chemical compositions and methods of making them | JR Chemicals (US) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | PARG, PCBP1, POLI | CA4 22/4885CASP1 3327/4885FFAR3 4783/4885 |
| US-20120177583-A1 | COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS | APC, ALPI, SLC10A2 | CA4 88/4885CASP1 4596/4885FFAR3 2689/4885 |
| US-20110178318-A1 | METHODS OF MAKING BIMETAL COMPLEXES | SOD1, PARG, PMS2 | CA4 198/4885CASP1 3961/4885FFAR3 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.